University of Michigan

Gwangseong Kim

Raoul Kopelman

Yong-Eun Koo Lee

Jerome Kalifa

Hyung Ki Yoon

Uma Mahesh R Avula

Russell Witte

Shai Ashkenazi

Thomas D Horvath

The present invention relates to nanoparticles. In particular, the present invention provides nanoparticles for clinical (e.g., targeted therapeutic), diagnostic (e.g., imaging), and research applications in the field of cardiology. For example, in some embodiments, the present invention provides a method of treating (e.g., ablating) cardiac tissue, comprising: a) contacting an animal with a nanoparticle comprising a matrix, a toxic (e.g., ablative) agent (e.g., sonosensitizer, chemotherapeutic agent (e.g., doxorubicin or cisplatin), or photosensitizer), and a cardiac targeting moiety; and b) administering an activator of the toxic agent (e.g., light, chemical (e.g., pharmaceutical agent) or ultrasound) to at least a portion of the cardiac tissue (e.g., heart) of the animal to activate the toxic agent.

Systems and methods for targeted imaging and ablation of cardiac cells

A method of measuring fluorophore excited state lifetimes comprising initiating an excitation laser pulse at a dye to excite dye molecules of the dye from a ground state to an excited state and initiating a probing pulse at the dye molecules thereby generating a first set of photoacoustic waves at a first time delay resulting in a first intensity point. The process can be repeated, optionally introducing a second excitation laser pulse, to generate a second set of photoacoustic waves at a second time delay resulting in a second intensity point. The data can be analyzed to determine a slope between the first intensity point and the second intensity point.

Photoacoustic indicators

Growing community of inventors

Ann Arbor, MI, United States of America

Gwangseong Kim